KING PHARMACEUTICALS PUBLISHES TRIAL RESULTS FOR ALTACE

King Pharmaceuticals has reported the publication of the results of the "Heart Outcomes Prevention Evaluation — The Ongoing Outcomes ("HOPE-TOO")." The HOPE- TOO results are published in an article entitled "Long-Term Effects of Ramipril on Cardiovascular Events and on Diabetes" which appears in the August 30 issue of Circulation, a publication of the American Heart Association.

After seven years of patient follow-up, the HOPE-TOO trial demonstrated the sustained effect of Altace, an angiotensin converting enzyme inhibitor, on reducing the risk of cardiovascular events and sustained vascular and metabolic benefits for patients treated with ramipril. The authors of the article also concluded that the data indicated that a patient's earlier use of ramipril therapy provided a longer-term protective effect compared with the later initiation of such therapy.